These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16619562)

  • 1. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study.
    Stathopoulos GP; Boulikas T; Kourvetaris A; Stathopoulos J
    Anticancer Res; 2006; 26(2B):1489-93. PubMed ID: 16619562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.
    Spunt SL; Freeman BB; Billups CA; McPherson V; Khan RB; Pratt CB; Stewart CF
    J Clin Oncol; 2007 Jun; 25(16):2274-80. PubMed ID: 17538173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
    Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
    Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
    Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
    Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
    Sastre J; Aranda E; Abad A; Gallego J; Manzano JL; Gómez A; Carrato A; López E; Díaz-Rubio E;
    Anticancer Drugs; 2006 Apr; 17(4):417-21. PubMed ID: 16549999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
    Kotsakis A; Kouroussis Ch; Androulakis N; Agelaki S; Kalbakis K; Vamvakas L; Vardakis N; Kalykaki A; Polyzos A; Georgoulias V; Mavroudis D
    Oncology; 2006; 71(3-4):190-6. PubMed ID: 17641537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A dose escalation study of concurrent chemoradiation therapy with nedaplatin for cervical cancer].
    Hatae M; Takahashi T; Kodama S; Nakayama H; Kuzuya K; Saji F; Kamiura S; Watanabe Y; Nishimura R; Kono I; Ariyosh Y; Fukuoka M; Imajo Y; Hasegawa K; Noda K; ;
    Gan To Kagaku Ryoho; 2005 Apr; 32(4):473-8. PubMed ID: 15853213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
    ; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
    J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dose-finding study of bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancer.
    Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama S; Nakatani K; Nishimura K; Shimoda T; Azuma M; Ishido K; Saigenji K
    Anticancer Res; 2006; 26(5B):3797-802. PubMed ID: 17094404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.